Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric carboxymaltose for iron deficiency in congestive heart failure
ACTRN12614000154606Phase 3Not yet recruiting
- Sponsor
- Fremantle Hospital
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ferric carboxymaltose in heart failure (HF) and iron deficiency anemia (IDA) (2 arms), sponsored by Fremantle Hospital. Primary endpoints: Change in patient symptoms by Patient Global Assessment, Change in New York Heart Association functional class and 1 more. Planned start Mar 2014; status: not yet recruiting.
02
Drugs
ferric carboxymaltose
03
Conditions
heart failure (HF)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on ACTRN12614000154606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000154606.